A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This is a randomised, double-blind, parallel group, multicentre clinical study to evaluate
the efficacy, safety, tolerability, pharmacokinetics and immunogenicity of SB5 compared to
Humira® in subjects with moderate to severe RA despite MTX therapy.